Literature DB >> 21258008

Hypoxia-inducible factors in human pulmonary arterial hypertension: a link to the intrinsic myeloid abnormalities.

Samar Farha1, Kewal Asosingh, Weiling Xu, Jacqueline Sharp, Deepa George, Suzy Comhair, Margaret Park, W H Wilson Tang, James E Loyd, Karl Theil, Raymond Tubbs, Eric Hsi, Alan Lichtin, Serpil C Erzurum.   

Abstract

Pulmonary arterial hypertension (PAH) is a proliferative vasculopathy characterized by high circulating CD34(+)CD133(+) proangiogenic progenitors, and endothelial cells that have pathologic expression of hypoxia-inducible factor 1 α (HIF-1α). Here, CD34(+)CD133(+) progenitor cell numbers are shown to be higher in PAH bone marrow, blood, and pulmonary arteries than in healthy controls. The HIF-inducible myeloid-activating factors erythropoietin, stem cell factor (SCF), and hepatocyte growth factor (HGF) are also present at higher than normal levels in PAH blood, and related to disease severity. Primary endothelial cells harvested from human PAH lungs produce greater HGF and progenitor recruitment factor stromal-derived factor 1 α (SDF-1α) than control lung endothelial cells, and thus may contribute to bone marrow activation. Even though PAH patients had normal numbers of circulating blood elements, hematopoietic alterations in myeloid and erythroid lineages and reticulin fibrosis identified a subclinical myeloproliferative process. Unexpectedly, evaluation of bone marrow progenitors and reticulin in nonaffected family members of patients with familial PAH revealed similar myeloid abnormalities. Altogether, the results show that PAH is linked to myeloid abnormalities, some of which may be related to increased production of HIF-inducible factors by diseased pulmonary vasculature, but findings in nonaffected family suggest myeloid abnormalities may be intrinsic to the disease process.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21258008      PMCID: PMC3072874          DOI: 10.1182/blood-2010-09-306357

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  52 in total

Review 1.  Hematopoiesis and angiogenesis: a link between two apparently independent processes.

Authors:  D Ribatti; A Vacca; L Roncali; F Dammacco
Journal:  J Hematother Stem Cell Res       Date:  2000-02

2.  Circulating endothelial progenitor cells, vascular function, and cardiovascular risk.

Authors:  Jonathan M Hill; Gloria Zalos; Julian P J Halcox; William H Schenke; Myron A Waclawiw; Arshed A Quyyumi; Toren Finkel
Journal:  N Engl J Med       Date:  2003-02-13       Impact factor: 91.245

Review 3.  Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

Authors:  Shahin Rafii; David Lyden; Robert Benezra; Koichi Hattori; Beate Heissig
Journal:  Nat Rev Cancer       Date:  2002-11       Impact factor: 60.716

4.  Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth.

Authors:  D Lyden; K Hattori; S Dias; C Costa; P Blaikie; L Butros; A Chadburn; B Heissig; W Marks; L Witte; Y Wu; D Hicklin; Z Zhu; N R Hackett; R G Crystal; M A Moore; K A Hajjar; K Manova; R Benezra; S Rafii
Journal:  Nat Med       Date:  2001-11       Impact factor: 53.440

5.  Unexplained pulmonary hypertension in chronic myeloproliferative disorders.

Authors:  D Dingli; J P Utz; M J Krowka; A L Oberg; A Tefferi
Journal:  Chest       Date:  2001-09       Impact factor: 9.410

Review 6.  Clinical applications of granulocyte colony-stimulating factor: an update and summary.

Authors:  K Hübel; A Engert
Journal:  Ann Hematol       Date:  2003-03-06       Impact factor: 3.673

7.  Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis.

Authors:  R M Tuder; M Chacon; L Alger; J Wang; L Taraseviciene-Stewart; Y Kasahara; C D Cool; A E Bishop; M Geraci; G L Semenza; M Yacoub; J M Polak; N F Voelkel
Journal:  J Pathol       Date:  2001-10       Impact factor: 7.996

8.  A gain-of-function mutation of JAK2 in myeloproliferative disorders.

Authors:  Robert Kralovics; Francesco Passamonti; Andreas S Buser; Soon-Siong Teo; Ralph Tiedt; Jakob R Passweg; Andre Tichelli; Mario Cazzola; Radek C Skoda
Journal:  N Engl J Med       Date:  2005-04-28       Impact factor: 91.245

9.  Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia.

Authors:  David P Steensma; C Christopher Hook; Scott L Stafford; Ayalew Tefferi
Journal:  Br J Haematol       Date:  2002-09       Impact factor: 6.998

10.  HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration.

Authors:  Christian Grimm; Andreas Wenzel; Matthias Groszer; Helmut Mayser; Mathias Seeliger; Marijana Samardzija; Christian Bauer; Max Gassmann; Charlotte E Remé
Journal:  Nat Med       Date:  2002-06-17       Impact factor: 53.440

View more
  63 in total

Review 1.  Discovery of a murine model of clinical PAH: Mission impossible?

Authors:  Zhiyu Dai; You-Yang Zhao
Journal:  Trends Cardiovasc Med       Date:  2016-12-15       Impact factor: 6.677

Review 2.  Inflammation in Pulmonary Arterial Hypertension.

Authors:  Timothy Klouda; Ke Yuan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

3.  Hemolysis-induced Lung Vascular Leakage Contributes to the Development of Pulmonary Hypertension.

Authors:  Olga Rafikova; Elissa R Williams; Matthew L McBride; Marina Zemskova; Anup Srivastava; Vineet Nair; Ankit A Desai; Paul R Langlais; Evgeny Zemskov; Marc Simon; Lawrence J Mandarino; Ruslan Rafikov
Journal:  Am J Respir Cell Mol Biol       Date:  2018-09       Impact factor: 6.914

4.  Bone Marrow-derived Cells Contribute to the Pathogenesis of Pulmonary Arterial Hypertension.

Authors:  Ling Yan; Xinping Chen; Megha Talati; Bethany Womack Nunley; Santhi Gladson; Tom Blackwell; Joy Cogan; Eric Austin; Ferrin Wheeler; James Loyd; James West; Rizwan Hamid
Journal:  Am J Respir Crit Care Med       Date:  2016-04-15       Impact factor: 21.405

5.  Bone Marrow-Derived Proangiogenic Cells Mediate Pulmonary Arteriole Stiffening via Serotonin 2B Receptor Dependent Mechanism.

Authors:  Nathaniel C Bloodworth; Cynthia R Clark; James D West; J Caleb Snider; Christa Gaskill; Sheila Shay; Christine Scott; Julie Bastarache; Santhi Gladson; Christy Moore; Reid D'Amico; Evan L Brittain; Harikrishna Tanjore; Timothy S Blackwell; Susan M Majka; W David Merryman
Journal:  Circ Res       Date:  2018-12-07       Impact factor: 17.367

Review 6.  The crossroads of iron with hypoxia and cellular metabolism. Implications in the pathobiology of pulmonary hypertension.

Authors:  Jeffrey C Robinson; Brian B Graham; Tracey C Rouault; Rubin M Tuder
Journal:  Am J Respir Cell Mol Biol       Date:  2014-12       Impact factor: 6.914

7.  Human primary lung endothelial cells in culture.

Authors:  Suzy A A Comhair; Weiling Xu; Lori Mavrakis; Micheala A Aldred; Kewal Asosingh; Serpil C Erzurum
Journal:  Am J Respir Cell Mol Biol       Date:  2012-03-15       Impact factor: 6.914

8.  Impaired right ventricular-pulmonary vascular function in myeloproliferative neoplasms.

Authors:  Emir C Roach; Margaret M Park; W H Wilson Tang; James D Thomas; Kewal Asosingh; Matt Kalaycio; Serpil C Erzurum; Samar Farha
Journal:  J Heart Lung Transplant       Date:  2014-09-28       Impact factor: 10.247

Review 9.  The role of redox signaling in epigenetics and cardiovascular disease.

Authors:  Gene H Kim; John J Ryan; Stephen L Archer
Journal:  Antioxid Redox Signal       Date:  2013-03-12       Impact factor: 8.401

Review 10.  Origin and production of inflammatory perivascular macrophages in pulmonary hypertension.

Authors:  Jonathan Florentin; Partha Dutta
Journal:  Cytokine       Date:  2017-08-30       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.